Premium
Antioxidant activity of allopurinol on copper‐catalysed human lipoprotein oxidation
Author(s) -
Lapenna Domenico,
de Gioia Sergio,
Ciofani Giuliano,
Cuccurullo Franco
Publication year - 1997
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(97)00521-8
Subject(s) - allopurinol , chemistry , antioxidant , copper , lipoprotein , thiobarbituric acid , metal , in vivo , glutathione , quenching (fluorescence) , biochemistry , cholesterol , enzyme , organic chemistry , fluorescence , lipid peroxidation , medicine , physics , microbiology and biotechnology , quantum mechanics , biology
We found that allopurinol, at therapeutically relevant concentrations (9–58 μM), significantly counteracted copper‐catalysed human non‐HDL lipoprotein oxidation, as assessed by thiobarbituric acid reactant content and kinetics of conjugated diene formation. Oxypurinol was ineffectual. Both drugs had no activity on metal‐independent, peroxyl radical‐induced lipoprotein oxidation. Specific fluorescence‐quenching experiments revealed that only allopurinol could interact with copper antagonizing metal binding to lipoproteins. Thus, therapeutic allopurinol concentrations can inhibit copper‐catalysed lipoprotein oxidation through metal complexation, suggesting some antioxidant‐antiatherogenic activity of the drug in vivo.